{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:34:40Z","timestamp":1791282880174,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To report the early visual outcomes of eyes with a variety of retinal conditions that were treated with intravitreal faricimab during routine clinical practice in Latin America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective multicenter case series of 757 eyes of 732 patients who underwent at least one intravitreal injection of faricimab and had a least 4 weeks of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our cohort consisted of 392 eyes with neovascular age-related macular degeneration (NV-AMD) (naive\u2009=\u2009105; prior tx\u2009=\u2009287); 225 with DME (naive\u2009=\u200974; prior tx\u2009=\u2009151); 50 with central retinal vein occlusion (CRVO) (naive\u2009=\u200929; prior tx\u2009=\u200921); 20 with previously treated branch retinal vein occlusion (BRVO) and 69 (naive\u2009=\u200925; prior tx\u2009=\u200944) with other conditions. After a mean follow-up of 26.6 weeks and 4 injections, eyes with treatment naive NV-AMD eyes gained 9.1 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) with a last mean treatment interval of 9.5 weeks. Previously-treated NV-AMD eyes gained 6.6 to 9.5 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00146 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) after a mean follow-up of 29 to 42 weeks and 3.8 to 4.3 injections with a last mean treatment interval of 9.2 to 12.1 weeks. In treatment naive diabetic macular edema (DME) eyes, after a mean follow-up of 24.8 weeks and 4.2 injections, there was a gain of 12 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) with a last mean treatment interval of 9.2 weeks. In previously-treated DME eyes after a mean follow-up of 27.2 to 44.2 weeks and 3.8 to 3.9 to injections, there was a gain of 6.1 to 11.7 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) with a last mean treatment interval of 9.6 to 15.2 weeks. Treatment-naive CRVO eyes gained 22.6 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00369) after a mean follow-up of 26.2 weeks and 3.7 injections. Previously treated CRVO eyes gained 9.8 letters (0.5233) after a mean follow-up of 21.8 weeks and 3.4 injections. Previously-treated BRVO eyes gained 5.4 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00862) after a mean follow-up of 28.1 weeks and 3.5 injections and a last treatment interval of 11.1 weeks. A total of 38 eyes discontinued treatment with faricimab and switched back to aflibercept. There were 3 cases of anterior uveitis that were treated with topical steroids. None of the eyes developed infectious endophthalmitis or occlusive retinal vasculitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The early Latin American experience with faricimab is promising. On average treated eyes had functional and anatomic gains from baseline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00804-7","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:47:19Z","timestamp":1771670839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early Latin American experience with faricimab for retinal diseases: FARI-LATAM study for the Pan-American collaborative retina study (PACORES) group"],"prefix":"10.1186","volume":"12","author":[{"given":"Lihteh","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Nehemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria H.","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jans","family":"Fromow-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Barraza-Lino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cardenas-Mir\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Gabela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Baldivieso-Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gabela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisseth","family":"Chinchilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Verdaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Zas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Garc\u00eda-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Abel","family":"Ramirez-Estudillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandsy","family":"Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazmin","family":"Baez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Arriola-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Marcelo","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"14","key":"804_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.62.14.26","volume":"62","author":"PA Campochiaro","year":"2021","unstructured":"Campochiaro PA. Retinal and choroidal vascular diseases: Past, Present, and future: the 2021 proctor lecture. Invest Ophthalmol Vis Sci. 2021;62(14):26.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"804_CR2","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1007\/s00417-021-05451-2","volume":"259","author":"P Lanzetta","year":"2021","unstructured":"Lanzetta P. Anti-VEGF therapies for age-related macular degeneration: a powerful tactical gear or a blunt weapon? The choice is Ours. Graefes Arch Clin Exp Ophthalmol. 2021;259(12):3561\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"804_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","volume":"127","author":"S Kiss","year":"2020","unstructured":"Kiss S, Campbell J, Almony A, et al. Management and outcomes for neovascular Age-Related macular degeneration: analysis of united States electronic health records. Ophthalmology. 2020;127(9):1179\u201388.","journal-title":"Ophthalmology"},{"issue":"4","key":"804_CR4","doi-asserted-by":"publisher","first-page":"e14746","DOI":"10.1111\/dme.14746","volume":"39","author":"T Peto","year":"2022","unstructured":"Peto T, Akerele T, Sagkriotis A, et al. Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study. Diabet Med. 2022;39(4):e14746.","journal-title":"Diabet Med"},{"issue":"5","key":"804_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","volume":"36","author":"JF Arevalo","year":"2016","unstructured":"Arevalo JF, Lasave AF, Wu L, INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION, et al. 5-Year results of the Pan-American collaborative retina study group. Retina. 2016;36(5):859\u201367.","journal-title":"Retina"},{"issue":"12","key":"804_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/bjophthalmol-2015-307950","volume":"100","author":"JF Arevalo","year":"2016","unstructured":"Arevalo JF, Lasave AF, Wu L, et al. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American collaborative retina study group. Br J Ophthalmol. 2016;100(12):1605\u201310.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"804_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10792-021-02077-5","volume":"42","author":"L Wu","year":"2022","unstructured":"Wu L, Acon D, Berrocal MH, et al. Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: results of the Pan-American collaborative retina study (PACORES) group. Int Ophthalmol. 2022;42(3):951\u20138.","journal-title":"Int Ophthalmol"},{"key":"804_CR8","doi-asserted-by":"crossref","unstructured":"Chen-Li G, Martinez-Archer R, Coghi A et al. Beyond VEGF: angiopoietin-tie signaling pathway in diabetic retinopathy. J Clin Med 2024;13(10).","DOI":"10.3390\/jcm13102778"},{"issue":"1","key":"804_CR9","doi-asserted-by":"publisher","first-page":"1967714","DOI":"10.1080\/19420862.2021.1967714","volume":"13","author":"M Surowka","year":"2021","unstructured":"Surowka M, Schaefer W, Klein C. Ten years in the making: application of crossmab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs. 2021;13(1):1967714.","journal-title":"MAbs"},{"issue":"10326","key":"804_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"10326","key":"804_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"issue":"8","key":"804_CR12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, et al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-Week results from the BALATON and COMINO trials. Ophthalmology. 2024;131(8):950\u201360.","journal-title":"Ophthalmology"},{"issue":"14","key":"804_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"8","key":"804_CR14","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","volume":"118","author":"DM Brown","year":"2011","unstructured":"Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from Ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594\u2013602.","journal-title":"Ophthalmology"},{"issue":"14","key":"804_CR15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"804_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal Aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201.","journal-title":"Ophthalmology"},{"issue":"7","key":"804_CR17","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","volume":"121","author":"JS Heier","year":"2014","unstructured":"Heier JS, Clark WL, Boyer DS, et al. Intravitreal Aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414\u2013e201.","journal-title":"Ophthalmology"},{"issue":"11","key":"804_CR18","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal Aflibercept for diabetic macular edema: 148-Week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376\u201385.","journal-title":"Ophthalmology"},{"issue":"20","key":"804_CR19","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"CR Group","year":"2011","unstructured":"Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","journal-title":"N Engl J Med"},{"issue":"1","key":"804_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and Anti-Vascular endothelial growth factor therapy intensity in neovascular Age-Related macular degeneration patients: A Real-World analysis of 49 485 eyes. Ophthalmol Retina. 2020;4(1):19\u201330.","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"804_CR21","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.oret.2024.05.017","volume":"8","author":"BL Kuo","year":"2024","unstructured":"Kuo BL, Tabano D, Garmo V, et al. Long-term treatment patterns for diabetic macular edema: up to 6-Year Follow-up in the IRIS(R) registry. Ophthalmol Retina. 2024;8(11):1074\u201382.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"804_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40942-022-00425-w","volume":"8","author":"L Wu","year":"2022","unstructured":"Wu L, Bordon AF, Charles M, et al. Intravitreal Aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin america: the AQUILA study. Int J Retina Vitreous. 2022;8(1):76.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"804_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40942-022-00396-y","volume":"8","author":"FJ Rodriguez","year":"2022","unstructured":"Rodriguez FJ, Wu L, Bordon AF, et al. Intravitreal Aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin america: the AQUILA study. Int J Retina Vitreous. 2022;8(1):52.","journal-title":"Int J Retina Vitreous"},{"key":"804_CR24","unstructured":"Society P-ARV. Advocating for improved treatment and outcomes for wet age-related macular degeneration. 2012."},{"issue":"11","key":"804_CR25","doi-asserted-by":"publisher","first-page":"e012819","DOI":"10.1136\/bmjopen-2016-012819","volume":"6","author":"H Hong","year":"2016","unstructured":"Hong H, Mujica OJ, Anaya J, et al. The challenge of universal eye health in Latin america: distributive inequality of ophthalmologists in 14 countries. BMJ Open. 2016;6(11):e012819.","journal-title":"BMJ Open"},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2020","unstructured":"Okada M, Mitchell P, Finger RP, et al. Non-adherence or non-persistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2020;128:234\u201347.","journal-title":"Ophthalmology"},{"issue":"1","key":"804_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, et al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023;12(1):92.","journal-title":"Syst Rev"},{"key":"804_CR28","doi-asserted-by":"publisher","first-page":"45081","DOI":"10.1038\/srep45081","volume":"7","author":"DS Ng","year":"2017","unstructured":"Ng DS, Yip YW, Bakthavatsalam M, et al. Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Sci Rep. 2017;7:45081.","journal-title":"Sci Rep"},{"issue":"6","key":"804_CR29","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1111\/aos.12401","volume":"93","author":"R Tuuminen","year":"2015","unstructured":"Tuuminen R, Haukka J, Loukovaara S. Poor glycemic control associates with high intravitreal angiopoietin-2 levels in patients with diabetic retinopathy. Acta Ophthalmol. 2015;93(6):e515\u20136.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"804_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1755-3768.2012.02473.x","volume":"91","author":"S Loukovaara","year":"2013","unstructured":"Loukovaara S, Robciuc A, Holopainen JM, et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol. 2013;91(6):531\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"804_CR31","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1111\/aos.12223","volume":"92","author":"R Tuuminen","year":"2014","unstructured":"Tuuminen R, Loukovaara S. Increased intravitreal angiopoietin-2 levels in patients with retinal vein occlusion. Acta Ophthalmol. 2014;92(2):e164\u20135.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"804_CR32","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388.","journal-title":"EMBO Mol Med"},{"key":"804_CR33","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022."},{"key":"804_CR34","unstructured":"Wykoff CC, Abreu F, Adamis AP et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 2022."},{"issue":"1","key":"804_CR35","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.xops.2021.100111","volume":"2","author":"N Eter","year":"2022","unstructured":"Eter N, Singh RP, Abreu F, et al. YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale. Ophthalmol Sci. 2022;2(1):100111.","journal-title":"Ophthalmol Sci"},{"issue":"6","key":"804_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.oret.2023.01.018","volume":"7","author":"K Sarici","year":"2023","unstructured":"Sarici K, Yordi S, Martin A, et al. Longitudinal quantitative Ultrawide-field fluorescein angiography dynamics in the RUBY diabetic macular edema study. Ophthalmol Retina. 2023;7(6):543\u201352.","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"804_CR37","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.xops.2025.100744","volume":"5","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Guymer R, Artignan A, et al. Real-World evidence for faricimab in neovascular Age-Related macular degeneration and diabetic macular edema: A scoping review. Ophthalmol Sci. 2025;5(4):100744.","journal-title":"Ophthalmol Sci"},{"issue":"17","key":"804_CR38","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013\u20096 month results. Eye (Lond). 2023;37(17):3574\u201381.","journal-title":"Eye (Lond)"},{"issue":"10","key":"804_CR39","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","volume":"261","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto H, Hoshino J, Nakamura K, et al. Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261(10):2945\u201352.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"804_CR40","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, et al. One-year outcomes and safety assessment of faricimab in treatment-naive patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14(1):11681.","journal-title":"Sci Rep"},{"key":"804_CR41","doi-asserted-by":"crossref","unstructured":"Hara C, Suzue M, Fujimoto S et al. Comparison of loading dose between aflibercept and faricimab for neovascular age-related macular degeneration. J Clin Med 2024;13(2).","DOI":"10.3390\/jcm13020385"},{"issue":"2","key":"804_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00417-023-06241-8","volume":"262","author":"M Maruyama-Inoue","year":"2024","unstructured":"Maruyama-Inoue M, Yanagi Y, Inoue T, Kadonosono K. Comparison of functional and morphologic changes between Brolucizumab and faricimab in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(2):589\u201399.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"804_CR43","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.2147\/OPTH.S468458","volume":"18","author":"D Modeste","year":"2024","unstructured":"Modeste D, Stewart C, Premanandhan H, et al. Evaluating faricimab in Treatment-Naive neovascular age related macular degeneration: A retrospective analysis of Real-World data. Clin Ophthalmol. 2024;18:2821\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"804_CR44","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13(1):8747.","journal-title":"Sci Rep"},{"key":"804_CR45","doi-asserted-by":"crossref","unstructured":"Matsumoto H, Hoshino J, Nakamura K, et al. Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol; 2023.","DOI":"10.1007\/s00417-023-06116-y"},{"issue":"1","key":"804_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, et al. Six-month outcomes of switching from Aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(1):43\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"804_CR47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00417-023-06319-3","volume":"262","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Rizzato A, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol. 2024;262(4):1151\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"16","key":"804_CR48","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, et al. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (Lond). 2024;38(16):3059\u201364.","journal-title":"Eye (Lond)"},{"key":"804_CR49","doi-asserted-by":"crossref","unstructured":"Ali FS, Tabano DC, Borkar DS et al. Early outcomes after initiation of faricimab for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 2025:1\u201310.","DOI":"10.3928\/23258160-20250304-02"},{"key":"804_CR50","doi-asserted-by":"crossref","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, et al. Real-World outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina; 2023.","DOI":"10.1016\/j.oret.2023.10.018"},{"key":"804_CR51","doi-asserted-by":"crossref","unstructured":"Szigiato A, Mohan N, Talcott KE, et al. Short-Term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior Anti-VEGF therapy. Ophthalmol Retina; 2023.","DOI":"10.1016\/j.oret.2023.08.018"},{"issue":"1","key":"804_CR52","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13(1):21128.","journal-title":"Sci Rep"},{"key":"804_CR53","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, et al. Initial Real-World experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"key":"804_CR54","doi-asserted-by":"crossref","unstructured":"Kenworthy MK, Alexis JA, Ramakrishnan P, Chen FK. Retreatment interval lengthening achieved in two thirds of eyes with prolonged intensive anti-VEGF therapy for neovascular age-related macular degeneration after switching to faricimab. Clin Exp Ophthalmol; 2023.","DOI":"10.1111\/ceo.14335"},{"key":"804_CR55","doi-asserted-by":"crossref","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, et al. Real-world outcomes of treatment resistant neovascular-age related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina; 2023.","DOI":"10.1016\/j.oret.2023.11.015"},{"issue":"3","key":"804_CR56","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/j.xops.2023.100442","volume":"4","author":"R Guymer","year":"2024","unstructured":"Guymer R, Bailey C, Chaikitmongkol V, et al. Rationale and design of VOYAGER: Long-term outcomes of faricimab and Port delivery system with Ranibizumab for neovascular Age-Related macular degeneration and diabetic macular edema in clinical practice. Ophthalmol Sci. 2024;4(3):100442.","journal-title":"Ophthalmol Sci"},{"key":"804_CR57","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2147\/OPTH.S424314","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One year results of faricimab for Aflibercept-Resistant diabetic macular edema. Clin Ophthalmol. 2023;17:2397\u2013403.","journal-title":"Clin Ophthalmol"},{"key":"804_CR58","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2147\/OPTH.S381503","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Faricimab for Treatment-Resistant diabetic macular edema. Clin Ophthalmol. 2022;16:2797\u2013801.","journal-title":"Clin Ophthalmol"},{"key":"804_CR59","doi-asserted-by":"crossref","unstructured":"Ohara H, Harada Y, Hiyama T et al. Faricimab for diabetic macular edema in patients refractory to Ranibizumab or Aflibercept. Med (Kaunas) 2023;59(6).","DOI":"10.3390\/medicina59061125"},{"issue":"13","key":"804_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/iovs.64.13.31","volume":"64","author":"Y Takamura","year":"2023","unstructured":"Takamura Y, Yamada Y, Morioka M, et al. Turnover of microaneurysms after intravitreal injections of faricimab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2023;64(13):31.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"804_CR61","doi-asserted-by":"crossref","unstructured":"Kusuhara S, Kishimoto-Kishi M, Matsumiya W et al. Short-Term outcomes of intravitreal faricimab injection for diabetic macular edema. Med (Kaunas) 2023;59(4).","DOI":"10.3390\/medicina59040665"},{"key":"804_CR62","doi-asserted-by":"publisher","first-page":"101973","DOI":"10.1016\/j.ajoc.2023.101973","volume":"33","author":"M Sawa","year":"2024","unstructured":"Sawa M, Nakagawa N, Shunto T, Nishiyama I. Two cases of diabetic macular edema with diminished areas of retinal non-perfusion and microaneurysms after intravitreal faricimab injections. Am J Ophthalmol Case Rep. 2024;33:101973.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"12","key":"804_CR63","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1007\/s12325-023-02675-y","volume":"40","author":"C Watkins","year":"2023","unstructured":"Watkins C, Paulo T, Buhrer C, et al. Comparative Efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: A systematic literature review and network Meta-Analysis. Adv Ther. 2023;40(12):5204\u201321.","journal-title":"Adv Ther"},{"key":"804_CR64","doi-asserted-by":"crossref","unstructured":"Borkar DS, Tabano DC, Ali FS et al. Early outcomes after initiation of faricimab in patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina 2025:1\u20139.","DOI":"10.3928\/23258160-20250304-01"},{"key":"804_CR65","doi-asserted-by":"crossref","unstructured":"Tahmasebi A, Ebrahimiadib N, Niyousha M, Hassanpoor N. Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol; 2025.","DOI":"10.1007\/s00417-025-06878-7"},{"key":"804_CR66","doi-asserted-by":"crossref","unstructured":"Hafner M, Herold TR, Kufner A et al. Switching to faricimab in Therapy-Resistant macular edema due to retinal vein occlusion: initial Real-World efficacy outcomes. J Clin Med 2025;14(7).","DOI":"10.3390\/jcm14072454"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00804-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00804-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00804-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:38:13Z","timestamp":1781635093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00804-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00804-7","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"This was a retrospective multicenter study that adhered to the tenets of the Declaration of Helsinki. Institutional review board approval was obtained at each participating center, if specifically required for a retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients signed an informed consent form if required for a retrospective study as determined by the institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L Wu (Roche C, L; Bayer C, L; Lumibird Medical C, L; Apellis C; Astellas C; Ocular Therapeutix C); S Rojas (Norlase L; Iridex L; Heidelberg Engineering L); X Rao (None); M Politis (None); JA Roca (Alcon L, AbbVie L, Bayer L, Lumibird L, Roche L); M Nehemy (Alcon L; Apellis; Bayer L; Janssen L; Astellas L; IQVIA L; Roche L); MH Berrocal (Genentech C, L; Alcon C, L; Lumibird L; Neurotech C); J Fromow-Guerra (Roche L; Bayer L; Industria Oftalmica SA L); K Barraza (Roche L; Iridex L; Heidelberg Engineering L); C Lopez (None); M Maia; A Cardenas (Bayer L, Roche L); G Gabela Alcon L, Roche L, Bayer L, Laboratorios Sophia (L); O Baldivieso-Hurtado (None); C Gabela (Bayer L, Roche L); L Chinchilla (Roche L); JI Verdaguer (None); M Zas (Alcon L; Bayer L; Abbvie L; Roche C, L; Novo Nordisk L); M Young (None); G Garcia-Aguirre (Alcon C, L; Abbvie C, L; Bayer C, L; Nidek C, L; Roche Genentech C, L, S); A Ramirez-Estudillo (Alcon L; Bayer L; Roche L); M Flores (None); N Abreu (Alcon L, Norlase L, Roche L); W Velez (None); Y Baez (Roche L; Nidek L); A Arriola (None); M Casella (Roche L, Zeiss L, Alcon L).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}